West Virginia Reaches Settlement with Juul Labs Inc.

Apr.11.2023
West Virginia Reaches Settlement with Juul Labs Inc.
West Virginia settles lawsuit with Juul for $7.9 million over allegations of unfair or fraudulent practices targeting minors.

The state of West Virginia has reached a settlement with e-cigarette manufacturer Juul Labs Inc. (hereafter referred to as Juul) over allegations that the company violated the state's consumer credit and protection laws.


Electronic cigarette manufacturer Juul has agreed to pay a $7.9 million settlement to the state. The company has been accused of engaging in unfair or deceptive practices, particularly targeted towards minors, in the manufacturing, design, sales, marketing, promotion, and distribution of e-cigarettes within the state. According to State Attorney General Patrick Morrisey, the settlement will prevent companies like Juul from adopting marketing strategies that target minors. Morrisey stated that the company was accused of deceiving consumers about the nicotine content, misrepresenting the nicotine equivalency between their products and traditional cigarettes, and underestimating the addictive risks associated with their high nicotine levels.


According to a statement from Austin Finan, Vice President of Corporate Communications for Juul Labs, this settlement represents "another step in Juul Labs' ongoing commitment to address the company's past issues.


According to Finan, the terms of the settlement agreement are similar to previous settlements and provide financial resources for further efforts to combat underage smoking and develop smoking cessation programs. This reflects the current business practices that have been implemented since the company's comprehensive relaunch in the fall of 2019. Given that West Virginia has the highest smoking rate in the United States, the company hopes that some of the funds will be directly used to reduce smoking and improve public health within the state.


According to Finan, Juul has reached a settlement with "40 states and regions, providing billions of dollars for participating states." As reported by 2FIRSTS before, Juul has already paid over $2.6 billion in settlements to different states. Finan stated, "This settlement is based on us resolving private lawsuits across the country and covers over 5,000 cases brought by approximately 10,000 plaintiffs.


According to data from the US Centers for Disease Control and Prevention (CDC), Juul e-cigarettes contain high levels of nicotine - the amount of nicotine in one Juulpod is equivalent to 20 regular cigarettes. However, the defense disagrees with this data, arguing that the total amount of nicotine in Juulpods is "equivalent to 1.72 packs (34 cigarettes).


The amount of nicotine contained in one Juulpod is equivalent to at least 20 regular cigarettes, according to a photo source provided by the Associated Press.


In 2017, 14.3% of high school students in West Virginia reported using e-cigarettes for at least one day in the past 30 days. This figure was slightly higher than the national average of 13.2%.


According to data from the 2019 National Youth Tobacco Survey, over 5 million American middle and high school students are currently using e-cigarettes, with 27.5% of high schoolers and 10.5% of middle schoolers reporting current use. Among these current e-cigarette users, 34.2% of high schoolers and 18% of middle schoolers use e-cigarettes for 20 or more days each month.


Related Reading:


2FIRSTS special: Juul settlement summary


JUUL has spent $18.2 billion in hopes of reaching a settlement. Here is a breakdown of the settlement amounts and conditions in each state.


Juul has reached a $24 million settlement agreement with Chicago.


A US district court has approved a $255m class-action settlement with Juul prior to trial.


E-cigarette company JUUL has paid a total of $1.7 billion in settlements after 34 states filed lawsuits against the company.


References:


The state of West Virginia has come to an agreement with e-cigarette company Juul.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
Trump Picks White House Health Policy Aide Heidi Overton to Lead FDA, Pending Senate Confirmation
U.S. President Donald Trump has chosen White House health policy aide Heidi Overton to lead the Food and Drug Administration, Bloomberg reported, citing a person familiar with the matter. Overton currently works on health policy at the White House and previously held a senior role at the America First Policy Institute. If confirmed by the Senate, she would take over an FDA that has experienced months of senior-level turnover. The agency regulates products representing roughly one-fifth of U.S. consumer spending, including e-cigarettes, drugs, vaccines and much of the food supply.
News
Aug.19